0.17
+3.13%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rainmed Medical
Its shares trade on HKEX under the ticker 2297.HK. It has been listed since 8 July 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥19.2m and a net loss of CN¥77.1m. At that date it held total assets of CN¥545.7m and shareholders' equity of CN¥357.5m.
Rainmed Medical Ltd. operates as a medical device company. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2022-07-08. The firm is primarily engaged in research and development, manufacturing and commercialization of medical instrument related to coronary angiography-derived fractional flow reserve (caFFR) system and coronary angiography-derived index of microvascular resistance (caIMR) system. The Company’s core products, caFFR system and caIMR system, are innovative medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment. The firm mainly operates its businesses in the domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 8 Jul 2022
- Employees
- 451
- Website
- rainmed.com ↗
Leadership
Pay as last reported
- Mr. Zeke ZhuJoint Chief Executive Officer, Executive Director, since 2025
- Mr. Yonghui LyuCo-Chief Executive Officer, since 2021CN¥24.9m
- Mr. Guangzhi LiuChief Technology Officer
- Mr. Xingyun WuVice President
- Mr. Chang ZhouVice President
- Ms. Jing DuanExecutive Director, since 2025
- Ms. Cheuk Ting ChuJoint Company Secretary
- Mr. Lei HengNon-Executive Director
- Dr. Yunlong HuoNon-Executive Director
- Mr. Lin WangNon-Executive Director
- Mr. Xuefeng ChenNon-Executive Independent Director
- Mr. Shuen Kong LiuIndependent Non-executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates as a medical device company with headquarters in Suzhou, Jiangsu.
- Employs 451 full-time employees.
- Core products include caFFR and caIMR systems for coronary artery disease evaluation.
Weaknesses
- IPO occurred in 2022, indicating a relatively new market presence.
- Relies on a limited product portfolio focused on specific medical devices.
- Primarily operates in domestic and overseas markets without specified market share details.
Opportunities
- Innovative medical devices for coronary artery disease evaluation may attract growing market demand.
- Potential for expansion in domestic and overseas markets with increasing healthcare needs.
- Research and development focus could lead to future product innovations.
Threats
- Competition in the medical device industry may impact market share.
- Dependence on specific medical conditions (CAD) could limit market growth potential.
- Reliance on R&D for product development may face regulatory or technical challenges.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.